Man K Chan
Overview
Explore the profile of Man K Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turkova A, Chan M, Kityo C, Kekitiinwa A, Musoke P, Violari A, et al.
Contemp Clin Trials
. 2024 Apr;
142:107540.
PMID: 38636725
Background: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of...
2.
Kim S, Schneidman-Duhovny D, de Groot P, Urbanus R, Carter L, de Laat-Kremers R, et al.
Thromb Res
. 2024 Apr;
237:145-147.
PMID: 38593525
No abstract available.
3.
Abdalla S, Compagnucci A, Riault Y, Chan M, Bamford A, Nolan A, et al.
Antimicrob Agents Chemother
. 2023 Dec;
68(2):e0100423.
PMID: 38092664
Darunavir (DRV) is an HIV protease inhibitor commonly used as part of antiretroviral treatment regimens globally for children and adolescents. It requires a pharmacological booster, such as ritonavir (RTV) or...
4.
Compagnucci A, Chan M, Saidi Y, Cressey T, Bamford A, Riault Y, et al.
EClinicalMedicine
. 2023 Jun;
60:102025.
PMID: 37304494
Background: Integrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen with a high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living with HIV (CLWHIV). Methods: SMILE...
5.
Turkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, et al.
Lancet HIV
. 2022 Jul;
9(9):e627-e637.
PMID: 35868341
Background: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated...
6.
Waalewijn H, Chan M, Bollen P, Mujuru H, Makumbi S, Kekitiinwa A, et al.
Lancet HIV
. 2022 Feb;
9(5):e341-e352.
PMID: 35189082
Background: Dolutegravir-based antiretroviral therapy is a preferred first-line treatment for adults and children living with HIV; however, very little pharmacokinetic data for dolutegravir use are available in young children. We...
7.
Payne H, Chan M, Watters S, Otwombe K, Hsiao N, Babiker A, et al.
AIDS Res Ther
. 2021 Sep;
18(1):63.
PMID: 34587974
Background: Reduction of the reservoir of latent HIV-infected cells might increase the possibility of long-term remission in individuals living with HIV. We investigated factors associated with HIV-1 proviral DNA levels...
8.
Chan M, Cooper J, Heilmann-Heimbach S, Frank J, Witt S, Nothen M, et al.
Sci Rep
. 2017 Oct;
7(1):12586.
PMID: 28974776
Genome-wide association studies (GWAS) and proteomic studies have provided convincing evidence implicating alterations in immune/inflammatory processes in schizophrenia. However, despite the convergence of evidence, direct links between the genetic and...
9.
Chan M, Cooper J, Bot M, Birkenhager T, Bergink V, Drexhage H, et al.
J Psychiatr Res
. 2016 Oct;
83:249-259.
PMID: 27693950
Antidepressant treatment for major depressive disorder remains suboptimal with response rates of just over 50%. Although treatment guidelines, algorithms and clinical keys are available to assist the clinician, the process...
10.
Ruland T, Chan M, Stocki P, Grosse L, Rothermundt M, Cooper J, et al.
Psychopharmacology (Berl)
. 2016 Jun;
233(15-16):3051-9.
PMID: 27325393
Rationale: A substantial number of patients suffering from major depressive disorder (MDD) do not respond to multiple trials of anti-depressants, develop a chronic course of disease and become treatment resistant....